The Bulk Drug Manufacturers Association of India (BDMAI) is set to roll out a dedicated e-marketing platform to promote Indian active pharmaceutical ingredients (APIs), intermediates, pellets, and pharma-related services to both domestic and global markets.

Aimed particularly at supporting small and medium enterprises (SMEs), the portal will enable bulk drug manufacturers to showcase their products and services digitally, thereby expanding their market reach through digitalisation.

The initiative will feature a specialised online application tailored for marketing APIs, intermediates, pellets, and associated pharma services such as contract development and manufacturing organisation (CDMO) offerings, consultancy, and reference standards. The app is expected to go live by September 2025 and will serve as a first-of-its-kind platform designed specifically for the Indian bulk drug ecosystem.

According to BDMAI’s national president R.K. Agarwal, the portal is intended to empower manufacturers by creating a centralised platform that facilitates greater visibility and access to national and international buyers. The move is aligned with BDMAI’s goal of promoting Indian bulk drugs globally with the support of central government departments.

M Roja Rani, executive director of BDMAI, confirmed that while the platform is an initiative of the association, participation is not restricted to its members. Non-member manufacturers and vendors will also be able to list their offerings.

"All members of BDMAI can display their company details like products, manufacturing facilities, accreditations, awards, and any other achievements, free of cost. Non-member manufacturers and traders also can showcase their products by paying prescribed charges,"  she said. 

“BDMAI will promote this Portal in India and in international markets on a continuous basis to promote the Indian Bulk Drugs Industry,” she added. 

Additionally, the platform will be open to allied service providers, including equipment manufacturers, packaging companies, and industry consultants. This integration will allow bulk drug manufacturers to not only market their products but also identify and engage relevant service providers through a single digital interface.

Buyers—both Indian and overseas—would be able to locate suppliers using product name, company name, HS code, or CAS number. They will also have the option to send inquiries to all or selected manufacturers and traders for the products they are looking for.

The portal will additionally provide space for vendors—such as suppliers of chemicals, equipment, instruments, maintenance items, IT services, and consultants—to register and display their products by paying prescribed charges.

Vendors can also send mailers about their products to the relevant departments of member and non-member companies.

This initiative represents a strategic leap toward enhancing India’s pharmaceutical manufacturing ecosystem and increasing its export competitiveness.

Established in 1991 and headquartered in Hyderabad, BDMAI represents a significant portion of India’s bulk drug manufacturers.